RSC Pharmaceutics

RSC Pharmaceutics is a gold open access journal launched by the Royal Society of Chemistry in 2024 that covers drug delivery, formulation and pharmaceutical technology, with a 2025 Journal Impact Factor of 5.5.《RSC 药剂学》（RSC Pharmaceutics）由英国皇家化学会于 2024 年创办，为金色开放获取期刊，覆盖药物递送、制剂与制药技术，2025 年影响因子为 5.5。

Scope

• The journal publishes research on emerging technologies and techniques in pharmaceutics, including drug delivery and enhanced drug targeting.本刊发表药剂学新兴技术与方法的研究，包括药物递送与增强的靶向给药。
• The formulation and design of medicines, and the design and characterisation of dosage forms, are core subjects.药物的处方与设计，以及剂型的设计与表征，是核心主题。
• The physicochemical and biological properties of drugs and of their carriers are treated at length.药物及其载体的理化性质与生物学性质受到重点讨论。
• Drug delivery devices and the mechanisms by which they release their payloads are covered.药物递送装置及其释放载荷的机制均有收录。
• Nanomedicine, biomaterials and vaccine delivery are prominent themes.纳米药物、生物材料与疫苗递送是其中的突出主题。
• Precision medicine and patient-specific formulation approaches are within scope.精准医学与面向个体患者的制剂方法均在其范围之内。
• The journal welcomes work at the interface of chemistry, materials science, biomedical sciences and pharmacy.本刊欢迎化学、材料科学、生物医学与药学交界处的研究。

History

• RSC Pharmaceutics is a new journal from the Royal Society of Chemistry, built around drug delivery, formulation and pharmaceutical technology.（RSC Pharmaceutics）是英国皇家化学会推出的新刊，围绕药物递送、制剂与制药技术构建。
• Yvonne Perrie of the University of Strathclyde was introduced as the founding editor-in-chief in September 2023.斯特拉思克莱德大学的 Yvonne Perrie 于 2023 年 9 月作为创刊主编亮相。
• The first volume appeared in 2024, and the journal reached its third volume in 2026.其第一卷于 2024 年出版，2026 年已进入第三卷。
• It is published on a gold open access model, so articles are free to read and are released under Creative Commons licences.本刊采用金色开放获取模式，文章可免费阅读，并以知识共享许可发布。
• It is indexed in the Emerging Sources Citation Index, Scopus and the Directory of Open Access Journals.本刊被新兴来源引文索引、（Scopus）与（Directory of Open Access Journals）收录。
• Its first impact factor of 5.5 was reported for 2025.其首个影响因子为 2025 年的 5.5。

Editors

• Yvonne Perrie, a professor of drug delivery at the University of Strathclyde, leads the journal as editor-in-chief.斯特拉思克莱德大学的药物递送教授 Yvonne Perrie 担任主编。
• Laura Fisher serves as executive editor at the Royal Society of Chemistry.英国皇家化学会的 Laura Fisher 担任执行编辑。
• The editorial board includes associate editors Clare Hoskins, Xiaoxuan Liu of China Pharmaceutical University, Heidi Mansour and Alexandros Sofias.编委会副编辑包括 Clare Hoskins、中国药科大学的 Xiaoxuan Liu、Heidi Mansour 与 Alexandros Sofias。
• Manuscripts are peer reviewed, and the reported median time to first decision is 19 days.稿件经同行评审，公布的首次决定中位时间为 19 天。
• Because the journal is fully open access, article processing charges apply and authors retain rights under a Creative Commons licence.由于本刊为完全开放获取，作者须支付文章处理费，并在知识共享许可下保留权利。
• The journal runs a blog and a paper-of-the-month series to highlight work published in its pages.本刊设有博客与「每月最佳论文」栏目，以推介其发表的成果。